2054-2055 / 2953
Conclusions
•
Ideally, in-vivo plan verification should be performed for all techniques
•
IMRT potentially pushes the delivery- and planning equipments to their
limits
•
Confidence in the whole chain should be built through, at least, patient-
specific pre-treatment plan verification
•
Convenient ’IMRT QA’ systems exist
•
Gamma analysis is useful for a high-throughput QA programme
•
Limitations of the gamma index require attention to dose deviation in
selected cases
•
Consider patient-specific QA as one among several important components
of the QA programme
05/04/2016